AZ and Biocompatibles enter GLP-1 alliance; later terminated
Executive Summary
AstraZeneca and drug delivery device firm Biocompatibles International PLC have entered into an agreement that gives AZ an exclusive option to license a new discovery-stage glucagon-like peptide (GLP-1; a naturally occurring hormone that stimulates the pancreas to produce insulin) analog and its patents for Type II diabetes and obesity.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice